Phase II Trial of Monoclonal Antibody (J591) in Combination With Low-Dose Subcutaneous Interleukin-2

NCT00040586 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

INDUSTRY

Sponsor class

Conditions

Prostatic Neoplasms

Interventions

DRUG: Monoclonal Antibody J591
DRUG: Recombinant Interleukin-2

Sponsor

BZL Biologics